Phase 2 N=10 Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Unresectable Malignant Neoplasm · Melanoma · Metastatic Melanoma
Primary: Resectability Rate — 8; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=4 Radiation and Combination Immunotherapy for Melanoma
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Phase 3 N=676 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 2 N=60 Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 68 percentage of participants
Phase 3 N=270 A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Melanoma
Primary: Progression Free Survival (PFS) — 122; 125 days — p=0.492
Phase 2 N=24 Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
Melanoma
Primary: Number of Patients With Objective Tumor Response (OR) to GSK2132231A Study Treatment — 2; 0; 0; 1 Participants
Phase 2 N=14 Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Recurrent Melanoma · Stage III Skin Melanoma · Stage IV Skin Melanoma
Primary: Response — 11 participants
Phase 2 N=20 Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Mucosal Lentiginous Melanoma · Acral Melanoma · Melanoma
Primary: 4-month Progression-Free Survival Rate — 0.27; 0.125 proportion of patients
Phase 3 N=402 Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Metastatic or Unresectable Cutaneous Melanoma
Primary: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 2.83; 1.51 Months — p=< 0.001
Phase 2 N=52 Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Phase 2 N=15 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Phase 1 N=33 Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Melanoma
Primary: Number of Patients With Severe Toxicities During the Study Treatment Period — 0 Participants
Phase 3 N=502 Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
Melanoma
Primary: Overall Survival (OS) — 11.17; 9.07 Months — p=0.0009
Phase 2 N=31 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients
Phase 2 N=101 Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Cancer · Melanoma
Primary: Progression Free Survival (PFS) — 148; 82 days — p=0.068
Phase 2 N=17 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Phase 2 N=169 Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
Melanoma (Skin)
Primary: Rate of 6 Month Progression-Free Survival — 18; 15; 4; 12 Participants
Phase 2 N=32 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Objective Response Rate Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) — 2 participants
Phase 2 N=183 A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
BRAF or NRAS Mutant Metastatic Melanoma
Primary: Percentage of Participants With Objective Response (OR) — 4.9; 14.5; 12.0 percentage of participants
Phase 2 N=39 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Phase 2 N=24 Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Metastatic Melanoma · Mucosal Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: Progression-free Survival (PFS) — 139; 94 days
Phase 2 N=95 Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Melanoma (Skin)
Primary: Progression-free Survival at 6 Months — 32.8; 56.1 % of patients alive and progression free
Phase 2 N=132 A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
Malignant Melanoma
Primary: Best Overall Response (BOR) Assessed by an Independent Review Committee Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 52.3 Percentage of participants
Phase 2 N=4 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
N/A N=6 A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Melanoma
Primary: Summary of Best Overall Response Following Twice Daily Administration of PL3397 at 1000 mg/Day In Participants With Unresectable or Advanced KIT-mutated Melanoma — 0; 1…
Phase 3 N=418 Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
Melanoma
Primary: Overall Survival (OS) — NA; 10.84 Months — p=<0.0001
Phase 2 N=49 Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Melanoma (Skin)
Primary: 9-week Progression-free Survival Rate — 0.44 proportion of patients
Phase 3 N=704 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Melanoma
Primary: Overall Survival (OS) — 26.0; 17.8 Months
Phase 2 N=32 Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Melanoma · Skin Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 18.8 Percentage of participants